Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study-Reference-Cited by-同舟云学术

Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study

Published:2022-11 Issue: Volume:176 Page:58-69
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Houvenaeghel Gilles^ORCID,de Nonneville Alexandre,Cohen Monique,Classe Jean-Marc,Reyal Fabien,Mazouni Chafika,Faure Christelle,Martinez Alejandra,Chauvet Marie-Pierre,Daraï Emile,Coutant Charles,Colombo Pierre-Emmanuel^ORCID,Gimbergues Pierre,Azuar Anne-Sophie,Rouzier Roman,Tunon de Lara Christine,Crochet Patrice,Rua Sandrine,Gonçalves Anthony^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years;Pan;N Engl J Med,2017

2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

3. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials;Lancet,2011

4. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials;Lancet,2015

5. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American society of clinical oncology clinical practice guideline focused update;Burstein;JCO,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment;Frontiers in Oncology;2023-12-15

2. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023;Bulletin du Cancer;2023-11